ArticleNuclear medicine communications2026
Retrospective analysis of [ 99m Tc]Tc-HYNIC-PSMA single photon emission computed tomography CT in patients with prostate cancer.
Article in Nuclear medicine communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Detection rate of [Frontiers in medicine · 2026Pooled it
- Patient selection for primary staging with [99mTc]Tc-PSMA SPECT/CT: influence of combined PSA and ISUP grade on detection of metastatic disease.European journal of nuclear medicine and molecular imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveProstate cancer is one of the most common malignancies in men. While multiparametric MRI is the gold standard for local staging of prostate cancer, accessibility may be limited. The same is true for Prostate Specific Membrane Antigen (PSMA) PET/computed tomography (CT). This study evaluates the diagnostic performance of [ 99m Tc]Tc-PSMA single photon emission computed tomography (SPECT) as an alternative molecular imaging modality.
methodsThis retrospective study of 82 patients with newly diagnosed prostate cancer compares the performance of [ 99m Tc]Tc-PSMA SPECT/CT with multiple readers, with MRI, and with respect to histopathological correlation from biopsies. SPECT/CT findings were evaluated both locally, using a standardised 12-segment prostate model, and with respect to metastases. Agreement between modalities and readers was measured using intraclass correlation and Cohen's kappa.
resultsPSMA SPECT/CT identified clinically relevant prostate lesions with the best interreader agreement for bone metastases and laterality, and poorest agreement for extraprostatic extension and seminal vesicle invasion. Sector-based comparison showed PSMA SPECT/CT to have comparable detection rates to MRI. Higher SPECT standardised uptake values (SUV) were associated with stronger concordance with biopsy results, higher than both the low SPECT SUV group and clinical MRI readings.
conclusion[ 99m Tc]Tc-PSMA SPECT/CT demonstrates promise as an alternative to MRI in the primary staging of prostate cancer, particularly in high SPECT SUV settings. While MRI remains more sensitive for local extension, PSMA SPECT may offer complementary value in comprehensive staging, especially in a resource-limited setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.